Companies in the pharmaceutical industry must shift from L1 (lowest-bid) costing to Life Cycle Cost Analysis (LCCA) to achieve long-term cost optimization, improve decision-making, and enhance sustainability
Shilpa Pharma Lifesciences, Unit-1, received EIR from USFDA
The product will be marketed by Dr. Reddy's
Dr. Reddy's Laboratories has reported total income of Rs. 8,016.2 crores during the period ended September 30, 2024
USFDA concludes inspection of Dr. Reddy's Laboratories R&D centre in Bachupally with zero observation
Dr. Reddy's Laboratories gets Form 483 from USFDA with 4 observations for API facility
ORACEA is a trademark of Galderma Holdings, S.A.
Versavo is the first Dr. Reddy's biosimilar product to be approved and launched in the UK
The acquisition is done through cash consideration, by way of conversion of SAFE (Simple Agreement for Future Equity) investment of US$ 2 Million to Preferred A-1 Shares
Dr. Reddy's Laboratories has been issued a Form 483 with three observations
Subscribe To Our Newsletter & Stay Updated
